Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-0877
- Development stage
- Discontinued
- Lead developer
- Eurofarma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**N-0877** is an investigational oral fixed-dose antihypertensive combination developed by Eurofarma for **essential arterial hypertension**. It combines an angiotensin receptor blocker with a thiazide diuretic; the individual active ingredients have not been publicly identified in the available trial record. The Phase 3 ATHESA study compares N-0877 with olmesartan + hydrochlorothiazide in adults with stage 2 primary arterial hypertension. ([ctv.veeva.com](https://ctv.veeva.com/study/phase-iii-randomized-double-blind-double-dummy-active-controlled-multicenter-study-on-the-effic))
- Brand names
- Karb HCTKanarb PlusTuvero
- Other names
- N 0877N0877N-0877
02
Targets
SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on N-0877.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-0877.